Embryonal rhabdomyosarcoma requires a combination of treatments, such as surgery, radiation therapy, and chemotherapy. Chemotherapy is required at all stages of rhabdomyosarcoma and is administered at different levels depending on the risk group. Chemotherapy plays a very important role in the treatment of embryonal rhabdomyosarcoma. Studies have shown that most embryonal rhabdomyosarcomas are sensitive to chemotherapeutic agents such as vincristine, actinomycin D, cyclophosphamide, and irinotecan, but the final outcome of chemotherapy varies according to individual differences. Rhabdomyosarcoma is the most common type of soft tissue sarcoma in children. It develops from abnormal growth of early muscle cells and can occur in various parts of the body. The World Health Organization classifies rhabdomyosarcoma into embryonal rhabdomyosarcoma, glandular rhabdomyosarcoma, and pleomorphic or mesenchymal rhabdomyosarcoma according to histological type, of which embryonal rhabdomyosarcoma accounts for 57% of all rhabdomyosarcoma cases and usually occurs in the head and neck, bladder, vagina, prostate, and testes. Embryonal is the best type of rhabdomyosarcoma in terms of prognosis.